The disposition of 1-(8- 
Introduction
Obesity is one of the most serious medical problems of the developed world, with over 1.6 of the adult population in the United States alone being overweight or obese. Overweight and obese people carry a higher risk for a variety of cardiovascular diseases, including hypertension, coronary heart disease, stroke, peripheral occlusive artery disease, type 2 diabetes, and cancer. Because of the rising prevalence of obesity and its ramifications, several drugs, including serotonin and noradrenaline inhibitors, lipase inhibitors, B3-adrenoreceptor agonists, leptin agonists, and melanocortin-3 agonists, have been developed. However, their use has been limited because of the presence of adverse events and patients' inability to retain weight loss after discontinuation of the therapy.
It has now been well established that the endocannabinoid systems (ECSs) play a key role in energy homeostasis by modulating both food intake and peripheral energy metabolism (Pagotto et al., 2006; Patcher et al., 2006; Akbas et al., 2009; Nogueiras et al., 2009) . In animals, the stimulation of ECSs influences metabolic pathways that lead to weight gain, dyslipidemia, hepatic steatosis, and insulin resistance through cannabinoid type 1 (CB1) receptor activation in brain and peripheral organs (Di Marzo and Matias, 2005; Kirkham, 2005; Richard and Boisvert, 2006) . Blockade of the CB1 receptor decreases food intake and induces weight loss in mouse and rat (Arnone et al., 1997; Colombo et al., 1998; Hildebrandt et al., 2003; Vickers et al., 2003; Di Marzo and Matias, 2005; Wiley et al., 2005; Kunos and Tam, 2011) . Therefore, CB1 receptor antagonists may be useful as anorectic drugs for the management of obesity and metabolic disease (Di Marzo, 2008; Kunos and Tam 2011) .
1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide 598 ) is a selective, highaffinity, and competitive CB1 receptor antagonist that inhibits both basal and cannabinoid agonist-mediated CB1 receptor signaling in vitro and in vivo (Hadcock et al., 2010) and was progressed into Phase 3 human clinical trials as an oral agent for the treatment of obesity (Griffith et al., 2009; Ragan et al., 2009; Hadcock et al., 2010) . It reduces acute food intake in rodents, decreases food intake and body weight in obese Beagle dogs and humans, and acutely stimulates energy expenditure in rats (Hadcock et al., 2010) .
The results from pharmacokinetics studies in rats and dogs suggested that CP-945,598 is well absorbed with a bioavailability of 32 to 60% and readily distributed throughout the body. Absorption, distribution, metabolism, and excretion studies with [
14 C]CP-945,598 in the mouse, rat, and dog resulted in good recovery of the radiolabeled dose, ranging from 98% in rat and mouse to 99% in the dog. The major route of excretion in all three species was via the biliary-fecal route. CP-945,598 is metabolized extensively in all three species, because no unchanged parent compound was detected in the urine across species and metabolism was the primary route of clearance (Miao et al., 2011) . The primary metabolic pathway was due to the oxidative N-deethylation to form an N-desethyl metabolite (M1), which was then subsequently metabolized to numerous novel and unusual metabolites. In humans, orally administered CP-945,598 is absorbed at a moderate rate (T max ϳ4 -6 h) and has a terminal phase T 1/2 of 107 to 163 h. The metabolic pathways of a drug candidate must be determined in humans to ensure that all the major human circulating metabolites have adequate coverage in preclinical species used for long-term safety evaluation studies (Baillie et al., 2002) . Recently, the U.S. Food and Drug Administration (http://www.fda.gov/CDER/ GUIDANCE/6897fnl.pdf) and International Conference on Harmonization (http://www.emea.europa.eu/pdfs/human/ich/028695en.pdf) suggested that additional toxicological testing on metabolites that have higher exposure in humans than preclinical species may be required. The objectives of the present study were to characterize the disposition of CP-945,598 in healthy obese male volunteers and to identify and quantify its excretory and circulating metabolites. A single dose of [ 14 C]CP-945,598 was orally administered to five human subjects. The urine, feces, and serum were collected and assayed for radioactivity and profiled for metabolites. The metabolites were separated on a reverse-phase HPLC system and analyzed by LC/MS and LC-MS/ MS, and, where possible, the proposed structures were supported by comparisons of their HPLC retention times and MS spectra with those of synthetic standards. Attempts were also made to determine the P450 enzyme responsible for the formation of major metabolites using human liver microsomes, recombinant P450 enzymes, and molecular docking.
Materials and Methods
General Chemicals. Commercially obtained chemicals and solvents were of HPLC or analytical grade. Kromasil C-18 and Luna C-18 analytical columns were obtained from Phenomenex (Torrance, CA). Ecolite(ϩ) scintillation cocktail was obtained from Valeant Pharmaceuticals (Costa Mesa, CA). Carbosorb and Permafluor Eϩ scintillation cocktails were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). HPLC-grade acetonitrile, methanol, and water and certified ACS-grade ammonium formate and formic acid were obtained from Thermo Fisher Scientific (Waltham, MA).
Radiolabeled Drug and Reference Standards. [ 14 C]CP-945,598 HCl, labeled at the C-8 position of the purinyl moiety (Fig. 1) , was synthesized by the radiochemistry group at Pfizer Global Research and Development (Groton, CT) using a standard procedure. It had a specific activity of 3.73 Ci/mg freebase equivalent and showed a radiochemical purity of Ͼ99%, as determined by HPLC using an in-line radioactivity detector. The synthetic reference compound standards 4-amino-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidine-4-carboxamide (CE-156,706, M1), 4-amino-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidine-4-carboxylic acid 764, M2) , and 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidin-4-one (CE-127,773, M5) were synthesized as described previously ( Fig. 1) (Miao et al., 2011) .
Human liver microsomes were obtained from XenoTech, LLC (Lenexa, KS) and stored at Ϫ70°C until used. HL-mix 13 was prepared by mixing liver microsomes from several donors to represent the P450 in normal human. Recombinant human P450 isoforms (CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5) were purchased from BD Gentest (Woburn, MA). The microsomal protein was assayed using the BCA assay kit (Pierce Chemical, Rockford, IL), and its P450 contents were determined by the method described previously (Omura and Sato, 1964) . ␤-NADP (reduced) was purchased from MP Biomedicals Inc. (Solon, OH).
Subjects and Dose Administration. Five healthy obese male subjects between the ages of 23 and 45 years participated in the study. Three subjects were black, one subject (3-1004) was mixed of black and Latino, and one subject (5-1009) was white. All subjects provided written, informed consent before participation in the study. The study protocol, consent documents, consent procedures, and subject recruitment procedures were approved by the Independent Institutional Review Board. The study was conducted in compliance with the International Conference on Harmonization Good Clinical Practices guidelines, the ethical principles that have their origin in the Declaration of Helsinki, and the U.S. Food and Drug Administration regulations for informed consent and protection of patient rights. The subjects entered the Clinical Research Facility (DaVita Clinical Research, Minneapolis, MN) 12 h before dosing and remained there for up to 672 h after dosing under continuous medical observation. All subjects had fasted at least 10 h and were given a single 25-mg oral dose of [ 14 C]CP-945,598 (ϳ94 Ci per subject). The dosing solution was prepared by dissolving the radiolabeled drug in water (100 ml). The drug was administered in an open fashion as a single oral dose in the morning. A standard meal was provided 4 h later. Subjects were required to refrain from lying down during the first 4 h after drug administration. Subjects were prohibited to consume caffeine-containing foods and/or beverages for 24 h before dosing and for 48 h after dosing. Administration of the study drug by or under the supervision of medical personnel ensured adherence.
Sample Collection and Storage. Each subject emptied their bladder and provided a 50-ml sample of urine immediately before dosing, which was frozen at or below Ϫ20°C. After dosing, urine samples were collected at 24-h intervals for up to 528 h for subject 1-1001, 624 h for subjects 2-1002 and 4-1007, 696 h for subject 3-1004, and 648 h for subject 5-1009. All of the urine collected during each time period was mixed, the total volume was recorded, and an aliquot was removed for storage at or below Ϫ20°C until analysis. After dosing, fecal samples were collected as passed for up to 552 h for subjects 1-1001 and 2-1002, 672 h for subject 3-1004, 624 h for subject 4-1007, and 600 h for subject 5-1009. At the end of study, all subjects had met preset release criteria; approximately 90% of the administered radioactivity was recovered from the urine and feces or 24-h urine, and fecal from 2 consecutive days had a radioactivity level of less than 1% of the total administered radioactivity. Venous blood samples (ϳ17 ml) for CP-945,598 concentrations 569 598 at ASPET Journals on November 6, 2017 dmd.aspetjournals.org and total radioactivity were collected from each subject in glass vacuum blood collection tubes before dosing (0) and at 1, 2, 4, 6, 24, 48, 96, 120, 168, 336 , and 504 h after dose. For the analysis of CP-945,598 metabolites, venous blood samples (ϳ45 ml) were collected from each subject as described above at 2, 4, 12, and 24 h after dose administration. All blood samples were centrifuged, and serum samples were collected in separated clean tubes. All these samples were stored at or below Ϫ20°C until analyzed.
Measurement of Total Radioactivity in Serum, Urine, and Feces. All measurements of total radioactivity were performed by liquid scintillation counting (LSC). Samples of serum (500 -4000 l in duplicate) and urine (ϳ500 l in triplicate) from each sampling time point were added to 10 to 15 ml of scintillation cocktail and counted in a liquid scintillation counter (Beckman Coulter, Fullerton, CA).
Fecal samples were transferred into tarred Stomacher 3500 bags, hydrated with water (1:4, w/v), and homogenized using a Stomacher homogenizer (Cooke Laboratory Products, Alexandria, VA). Triplicate aliquots (ϳ0.500 g) of each fecal homogenate were weighed into Combust cones, air dried, and combusted in an oxidizer equipped with a Packard Oximate 80 robot (model 307; PerkinElmer Life and Analytical Sciences, Boston, MA). The liberated 14 CO 2 was trapped in 9-ml Carbo-SorbE, diluted with 10 ml of PermafluorEϩ scintillation cocktail (PerkinElmer Life and Analytical Sciences), and counted in a PerkinElmer Wallac 1409 liquid scintillation counter (PerkinElmer Life and Analytical Sciences). The combustion efficiency of the sample oxidizer was determined by comparing the radioactivity recovered from replicate oxidations of control samples fortified with a known amount of [
14 C] to that obtained by direct fortification of the Carbo-Sorb/Permafluor trapping solution with the same amount of [ 14 C]. LSC data (in dpm) were automatically corrected for counting efficiency using an external standardization technique and instrument stored quench curve generated from a series of sealed quench standards in Ultima-Gold or Carbo-Sorb/Permafluor cocktails. Radioactivity less than twice the background value was considered to be below the limit of determination. Fecal samples collected before dosing were used as the control samples and provided the background count rate.
The actual dose of radioactivity administered to each subject was determined by measuring the residual radioactivity in the dosing container after dose administration and subtracting this from the total radioactive dose in the dosing container. When determining the amount of radioactivity excreted in urine and feces at each time point as a proportion of the amount administered, the net radioactivity in the actual dose was considered to be 100%. The amount of radioactivity in serum at each time point was calculated using the specific activity of the dose administered and was expressed as the nanogram equivalent of parent drug per milliliter.
Extraction of Metabolites from Biological Samples. Urine samples were pooled from 0 to 384 h for each subject in proportion to the volume of samples collected at a different collection interval; the radioactivity in the sample pool represented ϳ91% of total radioactivity excreted in urine. To remove the urine sediments, 50 ml of pooled urine sample was filtered through a syringe filter disc (Acrodisk syringe filter, 25 mm, 1, glass fiber disk, 10 ml of urine per disk). The urine filtrate was loaded onto a preconditioned SPE cartridge (Isolute C8, 5 g, 25 ml) and eluted with 15 ml of methanol, followed by an additional 15 ml of 0.5% ammonium hydroxide in acetonitrile. The elution solvents were then combined, and a 0.5-ml aliquot was counted by LSC to determine the extraction efficiency. The mean recovery was approximately 88%. The elution solvent was evaporated under nitrogen at 35°C to dryness in a Turbo Vap evaporator (Zymark Corp., Hopkinton, MA). The residue was reconstituted with 0.8 ml of methanol, vortexed, and centrifuged for 5 min at 14,000 rpm. The recovery of radioactivity in the final solution after reconstitution was Ͼ90%. An aliquot (100 l) of the supernatant was injected onto HPLC column and analyzed by a LC-ARC system (AIM Research, Hockessin, DE).
Fecal homogenates were pooled up to 504 h in proportion to the amount of samples collected at different collection intervals to represent approximately 92% of total radioactivity excreted in feces. A pooled fecal sample (40 g) was transferred to a 500-ml Erlenmeyer flask that contained 200 ml of acetonitrile, and then the flask was sonicated for 15 min and vigorously shaken in a 37°C water bath for 3 h. The sample mixture was allowed to settle, and the supernatant was filtered into a clean flask. The remaining residue was extracted with an additional 140 ml of 0.5% ammonium hydroxide in acetonitrile. The filtrates were combined, and a 1-ml aliquot was counted for radioactivity by LSC. The mean extraction recovery was estimated to be 89%. The organic solvent was evaporated to dryness under the nitrogen in a Turbo Vap evaporator. The residue was reconstituted with 5 ml of methanol, and an aliquot of 50 l was injected onto HPLC column and analyzed by a LC-ARC system. Serum samples (9 -14 ml) at 4, 12, and 24 h after dose from each subject were added dropwise to 80 ml of acetonitrile, vortexed, and sonicated for 30 min, and the mixtures were vigorously shaken in a 37°C water bath for 1 h. After centrifugation, the supernatants were separated into the clean 50-ml Falcon polypropylene conical tubes. The pellets were extracted with an additional 50 ml of acetonitrile containing 0.5% ammonium hydroxide. Serum samples at 48 h after dose for five subjects were pooled together (ϳ1 ml from each subject) and extracted twice with 15 ml of acetonitrile after the aforementioned procedure. The supernatants were combined, and aliquots (1 ml) were quantified by LSC. The recoveries were determined to be 84, 93, 91, and 79% for serum samples at 4, 12, 24, and 48 h after dose, respectively. The supernatants were evaporated to dryness under nitrogen in a Turbo Vap evaporator. The residues were then reconstituted with 0.4 ml of DMSO/H 2 O mixture (1:1) and analyzed by LC-ARC. The serum samples at 48 h from all subjects were pooled by volume and analyzed in a similar way.
In Vitro Studies of CP-945,598 Metabolism. Human liver microsomes and recombinant human P450s incubations. Human liver microsomes and recombinant P450 isoforms were reconstituted in 100 mM potassium phosphate buffer, pH 7.4. [
14 C]CP-945,598 (10 M, 0.15 Ci of radiocarbon) was preincubated with microsomes (0.5 M P450) or recombinant enzyme (20 pmol/ml) for 3 min at 37°C in a shaking water bath. The incubation was initiated with the addition of 100 l of cofactor (1 mM NADPH, 10 mmol MgCl 2 ) per 1 ml of incubation mixture. After 60 min, the incubations were terminated by the addition of 4 volumes of acetonitrile to the incubation mixture. The mixture was vortexed for 15 min and centrifuged at 2200 rpm for 15 min. The supernatant was transferred to a clean test tube and evaporated to dryness under a stream of nitrogen in a 37°C water bath. The residue was reconstituted with 250 l of 25% acetonitrile in water. Aliquots (50 l) were injected onto the HPLC.
Quantitative assessment of metabolites. Metabolite quantification from urine, feces, and serum was performed by measuring the areas of individually separated HPLC peaks detected using the LC-ARC system (AIM Research). The LC-ARC system was operated at a stop-flow mode with a 1.2-ml liquid flow cell. The counting time was 60 s for each 20-s fraction.
Metabolite quantification from in vitro incubations was performed using a ␤-RAM (IN/US Systems, Tampa, FL) and the Laura program (version 3.1.1.39; LabLogic System Ltd., Sheffield, UK). The ␤-RAM provided integrated peak representation in counts per minute and the percentage of total radioactivity comprised by the each peak within the radiochromatogram. The ␤-RAM was operated in the homogeneous liquid scintillation counting mode with the addition of 3 ml/min Tru-Count (IN/US) scintillation cocktail to the HPLC effluent.
High-performance liquid chromatography. The HPLC system consisted of a HP-1100 quaternary solvent delivery pump, a HP-1100 membrane degasser, a HP-1100 autoinjector, a HP-1100 photodiode array detector (Hewlett Packard, Palo Alto, CA), and an IN/US radioactive monitor (␤-RAM). Chromatography was performed on a Kromasil C-18 column (5 m, 4.5 ϫ 150 mm) with a mobile phase containing a mixture of 5 mM ammonium formate, pH 3.0 (solvent A) and acetonitrile (solvent B). The mobile phase was initially composed of solvent A/solvent B (80:20). The mobile-phase composition was then linearly programmed to solvent A/solvent B (65:35) over 35 min and changed to solvent A/solvent B 60:40 over 5 min. A gradient was programmed to solvent A/solvent B (20:80) over 10 min and 10:90 over 2 min. The mobile-phase composition was returned to the starting solvent mixture over 1 min. The system was allowed to equilibrate for approximately 7 min before making the next injection. The flow rate was 1.0 ml/min, and the separation was achieved at ambient temperature.
For serum, four consecutive injections (100 l each, 0.5 min apart) were made onto the column to accomplish one profiling analysis. During the first three injections, the HPLC system was operated at a flow rate of 0.2 ml/min with a mobile phase consisting of ammonium formate buffer/acetonitrile (97:3). After the fourth injection, the HPLC system resumed the normal gradient program as described above.
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For in vitro metabolites, the mobile phase was initially composed of solvent A/solvent B (80:20). The mobile-phase composition was then linearly programmed to solvent A/solvent B (60:40) over 30 min and changed to solvent A/solvent B 50:50 over 8 min. A short gradient was programmed to solvent A/solvent B (20:80) over 2 min. The mobile-phase composition was returned to the starting solvent mixture over 3 min. The system was allowed to equilibrate for approximately 7 min before making the next injection. The flow rate was 1.0 ml/min, and the separation was achieved at ambient temperature.
LC-MS/MS. Identification of the metabolites was performed on a ThermoFinnigan LTQ ion trap mass spectrometer (Thermo Fisher Scientific) operating with electrospray. The effluent from the HPLC column was split, and ϳ50 l/min was introduced into the API interface. The remaining effluent was directed to the flow cell of ␤-RAM. The ␤-RAM response was recorded in real time by the mass spectrometer that provided simultaneous detection radioactivity and mass spectrometry data. The interface was operated at 5000 V, and the spectrometer was operated in the positive ion mode with a capillary temperature set at 250°C. Mass spectrometric data analysis was performed using Xcalibur version 1.4 vSR1 (Thermo Fisher Scientific).
Pharmacokinetic analysis. Serum concentrations of CP-945,598 and CE-156,706 (M1) were determined at PPD Development (Richmond, VA) using a validated LC-MS/MS assay (Miao et al., 2011) . Pharmacokinetic parameters were determined using the WinNonlin version 3.2 program (Pharsight, Mountain View, CA). Maximum observed concentrations (C max ) of CP-945,598; M1; or total radioactivity (parent drug equivalents) in serum were estimated directly from the experimental data, with T max defined as the time of first occurrence of C max . Terminal-phase rate constants (k el ) were estimated using least-squares regression analysis of the serum concentration-time data obtained during the terminal log-linear phase. Half-life (T 1/2 ) was calculated as 0.693/ k el . Area under the serum concentration-time curve from time 0 to the last time (t) with a measurable concentration (AUC (0-t) ) was estimated using the linear trapezoidal rule. AUC from time t to infinity [AUC (t-ϱ) ] was estimated as C est /k el , where C est represents the estimated concentration at time t based on the aforementioned regression analysis. AUC from time 0 to infinity [AUC (0-ϱ) ] was estimated as the sum of AUC (0-t) and AUC (t-ϱ) values.
Molecular and Quantum Mechanics-Based Modeling. The chemical structures of CP-945,598 and its desethyl metabolite M1 were generated by Chem3D (CambridgeSoft Corporation, Cambridge, MA), with geometries optimized using the molecular mechanics method MM2. The derived molecular structures were further optimized and computed using the quantum mechanics-based spin-unrestricted B3LYP (Becke three-parameter Lee-YangParr) density functional theory (DFT) method in the Gaussian 09 program package (Gaussian, Inc., Wallingford, CT). The basis set 6-31G**, a split valence basis set with polarization functions added on both heavy atoms and hydrogens, which was found to be a reliable approach to predict the aliphatic carbon hydrogen abstraction by cytochrome P450s Scott, 2010, 2011) , was implemented in this study. The carbon radical intermediates formed at the aliphatic carbons of CP-945,598 and M1 were optimized by the same method by removing a hydrogen atom with the activation energy calculated accordingly.
To prepare for the docking input files, the energetically minimized structures of CP-945,598 and M1 by DFT were further modified by AutoDockTools (The Scripps Research Institute, La Jolla, CA). The Gasteiger atomic charges were assigned with flexible torsions defined for CP-945,598 and M1. The protein template was recalculated based on a series of the X-ray crystallography-determined three-dimensional coordinates of CYP3A4 in the Protein Data Bank (codes 1TQN, 1W0E, 1W0F, 1W0G, 2J0D, 2V0M, and 3NXU) and Pfizer's Protein Structure Database (Sun et al., 2009a,b; Sun and Scott, 2011 ). An oxygen atom was added on top of the heme iron at a distance of 1.7 Å to simulate P450 compound I. The template was further modified with polar hydrogens, Kollman partial charges, and solvation parameters added using AutoDockTools. In addition, AutoGrid 4.0 (The Scripps Research Institute) was applied to define the substrate binding space in CYP3A4, a 60 ϫ 80 ϫ 80 Å cubic region covering the active site cavity above the heme porphyrin, and to calculate the grids of van der Waals, hydrogen bonding, electrostatic, torsional, and solvation interactions for each ligand atom. Docking was accomplished on Pfizer's high-performance computing Linux clusters using a Lamarckian genetic algorithm in AutoDock 4.0 (The Scripps Research Institute), which searches the globally energetically optimized conformations and orientations of CP-945,598 and M1. A total of 100 million evaluations were performed for each output binding pose, followed by clustering 200 poses by a root-mean-square deviation method. The lowest energy poses in the proximity of heme were chosen for analysis and visualized by PyMOL (Schrödinger, Inc., Portland, OR).
Results
Urinary and Fecal Excretion and Mass Balance. After a single dose of CP-945,598 to human subjects, the majority of the radioac- at ASPET Journals on November 6, 2017 dmd.aspetjournals.org tivity was excreted in the feces (Table 1) , with a mean total of 46.1 Ϯ 12.2% (S.D.) of the radioactivity at 672 h after dose administration. A mean total of 60.1 Ϯ 12.8% (S.D.) of the radioactivity was excreted in the urine and feces over a period of 672 h after dose administration. The mean urinary recovery was 14.0 Ϯ 3.32%. The cumulative mean (ϮS.D.) recovery of administered radioactivity in urine and feces is shown in Fig. 2 . Excretion of radioactivity via urine and feces continued for a considerable period of time, with Ͼ20% being excreted during the period 168 to 672 h after dose administration. It was noted that, for the majority of subjects, there were several days when no fecal sample was collected over the duration of collection period. Pharmacokinetics of CP-945,598; M1; and Total Radioactivity. The mean (ϮS.D.) concentration-time profiles of CP-945,598; M1; and total radioactivity in serum of humans after oral administration of [ 14 C]CP-945,598 are graphically depicted in Fig. 3 . After a single oral dose, serum concentrations of CP-945,598; M1 (CE-156,706); and total radioactivity peaked at 6.0, 6.8, and 6.0 h, respectively. The mean (ϮS.D.) C max values for CP-945,598; M1; and total radioactivity were 13.6 Ϯ 3.1 ng/ml, 42.4 Ϯ 6.4 ng/ml, and 74.1 Ϯ 9.6 ng-equiv/g, respectively ( Table 2 ). The mean (ϮS.D.) T 1/2 values for CP-945,598; M1; and total radioactivity were 159 Ϯ 33.0, 139 Ϯ 20.4, and 190 Ϯ 18.4 h, respectively. The mean (ϮS.D.) AUC( 0 -504h ) values for CP-945,598; M1; and total radioactivity were 778 Ϯ 223 ng ⅐ h Ϫ1 ⅐ ml Ϫ1 , 3731 Ϯ 317 ng ⅐ h Ϫ1 ⅐ ml Ϫ1 , and 8298 Ϯ 779 ng equiv.h/g, respectively. The AUC 0 to 504 ratios of CP-945,598 to total radioactivity suggest that Ͼ90% of the total circulating radioactivity was attributable to the metabolites (Table 2) .
Quantitative Profiles of [ 14 C]CP-945,598 and Metabolites in Serum and Excreta. Serum. The representative HPLC-radiochromatograms of serum at 4, 12, 24, and 48 h are shown in Fig. 4 . CP-945,598 and a total of three metabolites were detected in the radioprofiles. The relative amounts of [ 14 C]CP-945,598 and metabolites, expressed as percentage of total radioactivity, are presented in Table 3 . N-Desethyl (M1) was the major circulating metabolite at all time points. The parent drug, M1, M4, and M5 accounted for 12.1, 57.3, 17.9, and 12.6% of the extracted circulating radioactivity over 0 to 48 h (Table 3) .
Urine and feces. The representative HPLC-radiochromatograms of urine and feces are shown in Fig. 5 . In addition to CP-945,598, a total of five metabolites were detected in the urine and feces. The relative amounts of [ 14 C]CP-945,598 and metabolites, expressed as the administered dose, in excreta are presented in Table 4 . The amide hydrolysis product carboxy-metabolite (M2, CE-114,764) was the major metabolite in both urine and feces and accounted for 5.4 and 30.9% of the administered dose, respectively. The other metabolites, M1, M3, and M6, accounted for 6.8, 1.8, and 2.4% of the dose in the combined excreta. Hydroxylamine glucuronide (M17) was detected only in the urine and represented 4.8% of the dose. Ribose conjugate (M9) accounted for 6.3% of the dose and was present only in the feces (Table 4) .
Identification of Metabolites. The fragmentation pattern of CP-945,598 standard was studied to facilitate the interpretation of the mass spectra of its metabolites. Its full scan MS displayed a protonated molecular ion (MϩH) ϩ at m/z 510; an isotopic peak at m/z 512 (ratio of 3:2) was also observed because of the presence of two chlorine atoms in the molecule. The product ion (MS 2 ) spectrum of m/z 510 showed a peak at m/z 493, which was formed by a loss of ammonia. (Fig. 6A) . High-resolution MS suggested that the prominent ion at m/z 465 resulted from the characteristic loss of the ethylamine as well as the loss of formamide (data not shown). The fragments at m/z 356 and 368 resulted from the cleavages across the piperidine ring. These ions were the diagnostic ions for the structural elucidation of metabolites.
Metabolite M1. M1 was detected in feces, urine, and serum. The protonated molecular ion of M1 was at m/z 482, and an isotopic peak was at m/z 484. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. Based on these data, this metabolite was proposed to be a product formed by N-dethylation of the N-ethyl group. M1 had an identical spectrum to that of CE-156,706 synthetic standard.
Metabolite M2. M2 was detected in feces and urine. The protonated molecular ion of M2 was at m/z 483. The odd MH ϩ ion suggested the loss of a nitrogen atom from the parent molecule. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 393, 410, 422, 436, 438, and 466 (Fig. 6B) . The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unmodified. M2 had an identical spectrum to that of the CE-114,764 synthetic standard. On the basis of these data, this metabolite was proposed to be a product formed by amide hydrolysis of M1. Metabolite M3. M3 was detected in the urine and feces. Its protonated molecular ion at m/z 498, 12 mass units less than the parent compound and 16 mass units higher than M1, suggested the single oxygenation to the M1. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 453, and 465 (Fig. 7A) . The ion at m/z 465 resulted from the loss of a hydroxylamine moiety. The ion at m/z 453 was produced by deamidation on the piperidine ring. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unsubstituted. On the basis of these data, M3 was identified as 1-[9-(4-chloro-phenyl)-8-(2-chloro-phenyl)-9H-purin-6-yl]-4-hydroxyamino-piperidine-4-carboxylic acid amide.
Metabolite M4. M4 was detected only in the serum. The protonated molecular ion of M4 was m/z 453, 57 Da less than the parent compound, suggesting that M4 was a cleaved product. The odd MH ϩ ion suggested the loss of a nitrogen atom from the parent molecule. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 383, and 435 (Fig. 7B) . The ion at m/z 435 resulted from the loss of a water molecule. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. Incubation of M5 (CE-127,773) with hydroxylamine in an ammonium acetate buffer, pH 4, produced a substance that had an identical spectrum and a similar retention time on HPLC to that of M4. On the basis of these data, M4 was identified as 1-[9-(4-chlorophenyl)-8-(2-chloro-phenyl)-9H-purin-6-yl]-piperidin-4-one oxime.
Metabolite M5. M5 was detected only in the serum. It showed a protonated molecular ion at m/z 438, 72 Da less than the parent compound, suggesting a cleaved product. Its MS 2 and MS 3 spectra showed fragment ions at m/z 329, 339, 356, and 368. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, 
C-radioactivity-derived serum concentrations and AUCs of CP-945,598 and its metabolites over 0 to 48 h
Serum concentrations (ng-equiv/g) were calculated using the multiple of 14 C-derived radioactivity and the extraction recovery corrected percentage radioactivity detected in HPLCradiochromatograms. Forty-eight-h plasma sample was pooled from each individual due to low radioactivity. 10.1 Ϯ 6.0 10.9 Ϯ 4.1 10.9 Ϯ 4.9 6.0 Ϯ NA 438 Ϯ 146.7 17.9 Ϯ 4.3 M5 4.5 Ϯ 1.6 3.6 Ϯ 1.8 7.2 Ϯ 4.0 9.7 Ϯ NA 309 Ϯ 95.7 12.6 Ϯ 3.0 NA, not available.
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org suggested that the dichlorophenyl purine moiety was unchanged. M5 had an identical spectrum to that of the CE-127,773 synthetic standard. On the basis of these data, M5 was identified as 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidin-4-one. Metabolite M6. M6 was detected in feces and urine. The protonated molecular ion of M6 was m/z 498, and an isotopic peak was at m/z 500 in the ratio of 3:2, suggesting that two chlorine atoms were present in the molecule. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 463, 480, and 481. The ions at m/z 481 and m/z 480 were due to loss of the NH 3 and water, respectively. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was not substituted. Isolated M6 was treated with titanium trichloride, and its retention time on HPLC and associated mass were unchanged, suggesting that M6 was not an N-oxide. On the basis of these data, this metabolite was proposed to be a product formed by hydroxylation of N-desethyl metabolite (M1).
Metabolite M9a. M9a was detected only in the feces. The protonated molecular ion of M9a was m/z 614. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 463, 482, 506, 536, 578, and 596 . The ions at m/z 596 and 578 resulted from the consecutive losses of H 2 O. M9a was generated by reaction of CE-156,706 with D-ribose in 0.1N NaOH overnight in a 50°C water bath. The reaction mixture contained a chromatographic peak that had a same retention time and similar MS 2 and MS 3 spectra as those of M9a. On the basis of these data, M9a was identified as a ribose conjugate of CE-156,706 (M1).
Metabolite M17. M17 was detected only in the urine. The protonated molecular ion of M17 was m/z 674, and an isotopic peak was at m/z 676 in the ratio of 3:2, suggesting that both chlorine atoms were present in the molecule. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 422, 436, 453, 465, and 498. The prominent ion at m/z 498 was formed by a characteristic loss (176 Da), suggesting that M17 was a glucuronide conjugate. The MS 3 (m/z 498) spectrum was identical to the MS 2 spectrum of M3 and suggested that M17 was a glucuronide conjugate of M3. On the basis of these data, M17 was identified as a glucuronide conjugate of hydroxylamine metabolite M3.
Quantitative Profiles of [ 14 C]CP-945,598 and Metabolites in Human Liver Microsomes and Recombinant P450 Enzymes. Representative HPLC-radiochromatograms of CP-945,598 and its metabolites from human liver microsomes and recombinant CYP3A4/3A5 enzymes are shown in Fig. 8 . CP-945,598 and five metabolites were detected in the human liver incubations. The percentages of metabolites are shown in Table 5 . N-Desethyl (M1) and hydroxyl amine (M3) were the major metabolites in human liver microsomes. M4, M5, and M6 accounted for 4.0, 2.5, and 2.3% of the total radioactivity. Only M1 was detected in recombinant human CYP3A4 and 3A5. No metabolite was detected in the incubation of CP-945,598 with CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 (data not shown).
Structure-Based Modeling of CP-945,598 and M1 with CYP3A4. The molecular docking studies showed that the N-ethyl moiety of CP-945,598, especially its methylene carbon, can access the heme iron-oxo in an energetically favored orientation (Fig. 9A) , within the active site space of CYP3A4 confined by the helix I, B-C loop, F-G loop, and K-␤ loop. We found the hydrophobic Ϫ stacking interactions between the pyrimidine ring of CP-945,598 and the side chain of phenylalanine-108 at the B-C loop (ϳ3.7 Å), as well as the potential formation of the hydrogen bond between the amide carbonyl group of CP-945,598 and the hydroxyl group of serine-119 at the B-C loop (ϳ3.3 Å between two oxygen atoms), juxtapose the methylene carbon over the heme iron-oxo (ϳ2.8Å from the carbon to the iron-oxo). The calculated activation energy of the methylene carbon is 97.24 kcal/mol (Table 6) , in a similar range as those previously reported for N-dealkylation reactions (Sun and Scott, 2011) . Thus, this binding pose suggests an N-deethylation pathway, which is indeed the predominant metabolic route we observed in our in vitro studies. In addition, the mechanism of the M1 formation indicates the methylene hydrogen abstraction may be more favored than the nitrogen electron abstraction, which is restrained by the piperidine ring. The electron withdrawing of the neighboring amide carbonyl group also increases the oxidation potential of the nitrogen atom. 575 598 at ASPET Journals on November 6, 2017 dmd.aspetjournals.org
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The chemical reactivity of other aliphatic carbons of CP-945,598 was also calculated, which indicates that the activation energy of the terminal methyl group of the N-ethyl moiety is approximately 11 kcal/mol higher than that of the methylene. In addition, the calculated activation energy of the piperidine carbon hydrogen abstraction was 105.3 and 97.71 kcal/mol (Table 6 ), but they are not accessible to the heme iron-oxo because of steric hindrance. For example, several hydrophobic residues of I helix prevent the N-ethyl moiety binding further down toward the heme porphyrin to expose the piperidine ring. Putting them together also suggests that the N-dealkylation should be a major metabolic pathway of CP-945,598, and the methylene hydrogen atom abstraction seems to be the mechanism.
The docking results of M1 suggest both the newly formed terminal amine group (Fig. 9B ) and the piperidine ring (Fig. 9C) can access the heme iron-oxo in energetically favored orientations. The terminal amine heme-access pose (ϳ2.6 Å from the amine nitrogen atom to the heme iron oxo) demonstrated similar molecular interactions as observed for CP-945,598, which may indicate a potential nitrogen oxidation pathway. In addition, the DFT calculation of the hydrogen atom abstraction of M1 showed that the piperidine nitrogen-side carbon hydrogen atom is approximately 7 kcal/mol lower than the one at the amide side; however, the steric effects favor the other way.
Discussion
In this study, we characterized the routes of elimination, metabolism, and excretion mass balance of [ 14 C]CP-945,598 after a single 25-mg oral dose to humans. A radioactivity dose of 100 Ci of [ 14 C]CP-945,598 was selected for this study based on radioactivity dosimetry estimations from the tissue distribution of [ 14 C]CP-945,598 in rats. A major portion of the administered radioactive dose was eliminated via the fecal (ϳ46%) route, and urinary elimination accounted for only ϳ14% of the dose. These results are consistent with data from the preclinical toxicology species, in which CP-945,598 was eliminated mainly in feces also (Miao et al., 2011) . However, the total recovery of administered radioactivity in humans was low (60%), in contrast to preclinical species in which the radioactive dose was quantitatively recovered (Ͼ97%). The exact reason for the low recovery in humans is not known, but it could be due to several reasons. In general, the recovery of radioactive dose in humans for majority of the compounds is found to be lower than the preclinical species (Roffey et al., 2007) . In addition, low recoveries of radioactivity have been observed for compounds, which are eliminated primarily via the feces (Roffey et al., 2007) . Low recovery of radioactivity in feces could also probably be due to the sporadic nature of collection in this period (no samples for several days) as a reflection of altered bowel function in these subjects. Other reasons of low recovery in human may be due to the long half-life of the total radioactivity (190 h) and/or possible adipose tissue uptake of total radioactivity followed by slow elimination.
Pharmacokinetic analysis of total radioactivity and unchanged CP-945,598 suggested that the absorption was slow as the serum concentrations of both peaked at 6.0 h. Serum concentrations of total radioactivity greatly exceeded those of CP-945,598 at all time points, indicating that systemic exposure [AUC (0-ϱ) ] to total radioactivity in serum was ϳ11-fold greater than the parent compound, CP-945,598, demonstrating that the majority of circulating radioactivity was attributable to metabolites. On the basis of C max and AUC (0-ϱ) values, the exposure of M1 was 3-to 5-fold higher than the parent drug. The elimination of total radioactivity; CP-945,598; and M1 was also slow as indicated by their long terminal elimination half-lives (190 h for total radioactivity; 159 h for CP-945,598; and 139 h for M1). The mean half-life estimate was appreciably longer for total radioactivity compared with parent CP-945,598 and its major metabolite, M1. This observation, together with greater systemic exposure observed for total radioactivity, could not be accounted for by CP-945,598 and the major metabolite M1 alone; it reflects the formation of other radiolabeled metabolites that persist in the circulation longer than the parent compound and M1. In addition, the similar half-life estimates for CP-945,598 and M1 also suggest that this metabolite is formation rate limited, whereas some other metabolites (associated with total radioactivity) may be elimination rate limited.
The urine and feces radiochromatograms also indicate that CP-945,598 is metabolized extensively because Ͻ1.6% of the administered dose was excreted unchanged in excreta. A total of eight metabolites were identified by LC-MS/MS (Prakash et al., 2007) , and, where possible, the proposed structures were supported by comparison of their HPLC retention times and MS 2 / MS 3 spectra with those of the synthetic standards. Based on the structure of metabolites, metabolic pathways of CP-945,598 in humans are shown in Fig. 10 . The primary metabolic pathway of CP-945,598 involved N-dethylation to form an N-desethyl metabolite (M1), which is then subsequently metabolized by amide hydrolysis to piperidine-4-carboxylic acid (M2), N-hydroxylation to hydroxyamino-piperidine-4-carboxamide (M3), piperdine ring hydroxylation to hydroxypiperidine-4-carboxamide (M6), and ribose conjugation to M9. M3 was further at ASPET Journals on November 6, 2017 dmd.aspetjournals.org metabolized to the novel and unusual oxime (M4) and keto (M5) metabolites. The major excretory metabolites were M1 and M2, accounting for 36.3% of the administered dose. Human circulating metabolites included M1, M4, and M5. All three human metabolites (M1, M4, and M5) were each present in serum of the preclinical toxicology species (rat, mice, and dog) (Miao et al., 2011) , and each metabolite was present in at least one of the animal species at exposures that were similar to or exceeded the human exposure. The most abundant circulating metabolite, M1, was pharmacologically inactive and, therefore, it is not expected to contribute toward the efficacy of the parent drug.
In this study, we identified two oxidative metabolites (M4 and M5) and a ribose conjugate (M9a), similar to those identified in rats and dogs (Miao et al., 2011) . Although, similar biotransformation of amino acids has been reported in higher plants (Halkier et al., 1989) , the formation of M4 in mammals is novel and, to our knowledge, has not been reported. It has also been shown that two Arabidopsis P450s, CYP79B2 and CYP79B3, metabolized an important intermediate indole-3-acetaldoxime, implicated in auxin biosynthesis, by decarboxylation and subsequent dehydrogenation (Halkier et al., 1989; Zhao et al., 2002) . Another possibility is via the hydroxylamine and nitrone formation pathway; for example, a previous study found indoline was biotransformed to an indoline nitrone that was tautomerized to produce N-hydroxyindole (Sun et al., 2007) . It seems that the M4 formation may be initiated from the nitrogen radical cation formation and then the oxygen rebound due to the lack of the vicinal carbon hydrogens, followed by the nitrone formation and decarboxylation. The exact mechanism and the enzyme(s) involved for the formation of M4 are under investigation at this time. 598 (M1) 
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Incubation of CP-945,598 with human liver microsomes resulted in the formation of five metabolites, M1, M3, M4, M5, and M6, similar to those observed in vivo. Incubation of CP-945,598 with recombinant human P450s showed that only CYP3A4 and 3A5 form the major metabolite, M1. Other recombinant P450s demonstrated low or no metabolism of 543 , suggesting that that CP-945,598 is eliminated primarily by CYP3A4/3A5-catalyzed metabolism. The human CYP3A family, accounting for ϳ50% of the total P450 in human liver, is clinically very important because it has been shown to metabolize a large number of drugs (Wrighton et al., 1996) . The human CYP3A subfamily includes CYP3A4, CYP3A5, CYP3A7 (Li et al., 1995) , and CYP3A43 (Domanski et al., 2001 ) as subfamily members. CYP3A4 is the major human liver CYP3A enzyme, whereas CYP3A5 is present in only ϳ10 to 30% of the human liver and CYP3A7 is only present in fetal liver. CYP3A5*1 is a polymorphic-expressed enzyme in which the allelic frequency of wild type is only 10 to 15% in whites and 50% in blacks (Daly, 2006) . Although it is not currently possible to make a quantitative extrapolation from recombinant CYP3A5 data because of the lack of an appropriate CYP3A5 probe substrate for the generation of relative activity factors, the low rate of metabolism of CP-945,598 by CYP3A5 compared with CYP3A4 suggests that no dosage adjustment will be needed in populations in which the expression of this polymorphic enzyme is high.
In conclusion, this open-label Phase I study has shown that CP-945,598 is well absorbed and metabolized extensively to multiple oxidative metabolites, primarily by P450-dependent pathways, and that the radiolabeled material is eliminated by the biliary-fecal route. All the human metabolites were present in all animal species used for long-term safety and carcinogenicity assessments.
